deltatrials
Unknown PHASE2 INTERVENTIONAL 3-arm NCT00285402

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study

Sponsor: Ariston Pharmaceuticals, Inc.

Updated 6 times since 2017 Last updated: Feb 6, 2008 Started: May 31, 2007 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Migraine and Migraine Disorders and is currently ongoing. Ariston Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 9 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ariston Pharmaceuticals, Inc.
Data source: Ariston Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .